Multiple phase-2 trials in men with biochemically-recurrent prostate cancer (BRPC) have assessed the impact of nonhormonal agents on PSA kinetics. We have previously demonstrated that changes in PSA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback